CVD: Final Policy Recommendations
These policy recommendations from the September 26, 2019 meeting reflect the main themes and points made during the Policy Roundtable discussion about how best to apply the evidence on rivaroxaban and icosapent ethyl to policy and practice associated with the treatment of cardiovascular disease (CVD). This conversation, which can be accessed here, immediately followed the Midwest CEPAC voting portion of the meeting.
The Policy Roundtable members included two patients, two clinical experts, two payers, and one representative from a pharmaceutical manufacturer. The discussion reflected multiple perspectives and opinions, and therefore, none of the statements below should be taken as a consensus view held by all participants. More information on Policy Roundtable participants, including biographical information and conflict of interest disclosures, can be found in ICER’s Final Evidence Report in Appendix G.
The roundtable discussion was facilitated by Steven Pearson, MD, MSc, President of ICER.View All Materials on this Topic or Go Back to View More Materials